Etomidate elicits anti-tumor capacity by disrupting the JAK2/STAT3 signaling pathway in hepatocellular carcinoma.
Cancer Lett
; 552: 215970, 2023 01 01.
Article
in En
| MEDLINE
| ID: mdl-36265652
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Chemoembolization, Therapeutic
/
Carcinoma, Hepatocellular
/
Etomidate
/
Liver Neoplasms
Limits:
Humans
Language:
En
Journal:
Cancer Lett
Year:
2023
Type:
Article
Affiliation country:
China